C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/18 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61K 51/10 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01) C07K 16/46 (2006.01) C07K 19/00 (2006.01) C12P 21/08 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01)
Patent
CA 2684906
The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
La présente invention concerne un procédé de production d'anticorps modifiant les maladies cancéreuses grâce à un nouveau paradigme de crible. En ségrégant les anticorps anticancéreux en utilisant la cytotoxicité des cellules cancéreuses comme point final, le procédé permet de produire des anticorps anticancéreux à des fins thérapeutiques et diagnostiques. Les anticorps peuvent contribuer à grader et à dépister un cancer, et peuvent être utilisés pour traiter des tumeurs primaires et des métastases tumorales. Ils peuvent être conjugués à des toxines, des enzymes, des composés radioactifs, et des cellules hématogènes.
Cechetto Lisa M.
Findlay Helen P.
Hahn Susan E.
Young David S. F.
F. Hoffmann-La Roche Ag
Gowling Lafleur Henderson Llp
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1862463